SCHEMBL25819902

SCHEMBL25819902

CCc1cccc(C2CC(=O)NC(=O)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
BRD4 O60885 2/20 0.43
CREBBP Q92793 2/20 0.43
KIF11 P52732 1/20 0.43
MGLL Q99685 2/20 0.42
ALOX5 P09917 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
PKM P14618 2/20 0.38
LMNA P02545 1/20 0.38
PARP1 P09874 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRL1 P41146 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18617800 0.84 PDE4A (0.52) CREBBPLMNAPDE4APDE4BPDE4C
SCHEMBL13454038 0.82 MAPT (0.55) DDB1CRBNMGLLALOX5SMN1; SMN2
SCHEMBL25935883 0.80 DDB1 (0.43) DDB1CRBNSMN1; SMN2NPC1
SCHEMBL296959 0.78 HTR2C (0.54) DDB1CRBNLMNA
SCHEMBL22805478 0.77 SIGMAR1 (0.47) SMN1; SMN2NPC1RAB9A
SCHEMBL25047806 0.76 PDE4A (0.43) DDB1CRBNMGLLALOX5SMN1; SMN2
SCHEMBL18616368 0.76 HTR2C (0.40) MGLL
SCHEMBL10131923 0.75 ESR2 (0.43) DDB1CRBNMGLLALOX5SMN1; SMN2
SCHEMBL30817379 0.75 ALDH1A1 (0.52) DDB1CRBNSMN1; SMN2NPC1RAB9A
SCHEMBL31348863 0.75 LMNA (0.51) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 DDB1 132/4885CRBN 2136/4885BRD4 903/4885
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 DDB1 132/4885CRBN 2136/4885BRD4 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.